Abstract 4930: Ki-67 serves as a prognostic marker in early gastric cancer, but not in advanced gastric cancer

32 Background: Endoscopic submucosal dissection (ESD) is used for the treatment of gastric adenoma as well as early gastric cancer. Gastric adenoma is a well-known precursor of gastric cancer. The aim of this study is to investigate the expression degree of p53 and Ki-67 in gastric adenoma can predict progression to gastric cancer. Methods: We analyzed p53 and Ki-67 expression degree in the tumor tissue of 16 gastric adenoma patients treated by ESD and 11 early gastric cancer patients treated by subtotal gastrectomy at Kangnam Sacred Heart Hospital of Hallym University between November 2008 and May 2009. According to the fraction of stained nuclei in tumor tissue, expression degree was classified as < 10% = negative, 10%∼33% = 1+, 34%∼66% = 2+, > 66% = 3+. Results: Mean age was 65.1 ± 11.5 years and mean tumor size was 33.7 ± 20.2mm. Among 16 gastric adenoma patients, low-grade dysplasia were 11 and high grade dysplasia were 5. p53 positivity was not different between gastric adenoma and gastric cancer, but Ki-67 positivity was significantly different between adenoma and cancer (p < 0.05). In addition, Ki-67 positivity was increasing tendency as the pathology progress from low grade dysplasia to cancer. Conclusions: Ki-67 positivity grade seems to be correlated with malignancy. High Ki-67 positivity in gastric adenoma can predict progression to gastric cancer. Even if endoscopic biopsy showed low grade dysplasia, additional ESD should be preferentially considered in lesions with high Ki-67 positivity. No significant financial relationships to disclose.

Download Full-text

Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center

The Scientific World JOURNAL ◽

10.1155/2014/418694 ◽

2014 ◽

Vol 2014 ◽

pp. 1-10 ◽

Cited By ~ 1

Author(s):

Zhen Sun ◽

Rui-Juan Zhu ◽

Gui-Fang Yang ◽

Yan Li

Keyword(s):

Gastric Cancer ◽

Cohort Study ◽

Neoadjuvant Chemotherapy ◽

Adverse Events ◽

Advanced Gastric Cancer ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

R0 Resection ◽

Ki 67 ◽

Lymph Nodes Dissection

Background/Aim. To evaluate the clinical efficacy of FOLFOX4 (5-fluomumcil/leucovorin combined and oxaliplatin) neoadjuvant chemotherapy for advanced gastric cancer (AGC).Patients and Methods. Fifty-eight AGC patients were enrolled in this retrospective cohort study, 23 in the neoadjuvant group and 35 in the adjuvant group. R0 resection, survival, and adverse events were compared.Results. The two groups were well-matched, with no significant differences in R0 resection rate (82.6% versus 82.0%) and number of lymph nodes dissection (16 (0–49) versus 13 (3–40)) between the two groups(P>0.05). The number of lymph node metastases in the neoadjuvant group (3 (0–14)) was significantly fewer than that in the adjuvant group (6 (0–27))(P=0.04). The neoadjuvant group had significantly better median overall survival (29.0 versus 22.0 months) and 3-year survival rate (73.9% versus 40.0%) than the adjuvant group(P=0.013). The positive expression rate of Ki-67 in the neoadjuvant group (40.0%, 8/20) was lower than that in the adjuvant group (74.2%, 23/31;P=0.015).Conclusion. The FOLFOX4 neoadjuvant chemotherapy could improve survival without increasing adverse events in patients with AGC.

Download Full-text

Feasibility and Safety of Totally Laparoscopic Radical Gastrectomy for Advanced Gastric Cancer: Comparison with Early Gastric Cancer

Journal of Gastric Cancer ◽

10.5230/jgc.2018.18.e17 ◽

2018 ◽

Vol 18 (2) ◽

pp. 152 ◽

Cited By ~ 1

Author(s):

Seungyeob Lee ◽

Hayemin Lee ◽

Junhyun Lee

Keyword(s):

Gastric Cancer ◽

Early Gastric Cancer ◽

Advanced Gastric Cancer ◽

Radical Gastrectomy ◽

Totally Laparoscopic

Download Full-text

Effect of Helicobacter Pylori on Plasma Metabolic Phenotype in Patients With Gastric Cancer

Cancer Control ◽

10.1177/10732748211041881 ◽

2021 ◽

Vol 28 ◽

pp. 107327482110418

Author(s):

Yan-Ping Wang ◽

Ting Wei ◽

Xiao Ma ◽

Xiao-Liang Zhu ◽

Long-Fei Ren ◽

...

Keyword(s):

Gastric Cancer ◽

Helicobacter Pylori ◽

Early Gastric Cancer ◽

Advanced Gastric Cancer ◽

Cancer Patients ◽

Cancer Progression ◽

Acid Metabolism ◽

Metabolic Phenotype ◽

Multivariate Statistical ◽

Gastric Cancer Patients

Background Although Helicobacter pylori (Hp) as high risk factor for gastric cancer have been investigated from human trial, present data is inadequate to explain the effect of Hp on the changes of metabolic phenotype of gastric cancer in different stages. Purpose Herein, plasma of human superficial gastritis (Hp negative and positive), early gastric cancer and advanced gastric cancer analyzed by UPLC-HDMS metabolomics can not only reveal metabolic phenotype changes in patients with gastric cancer of different degrees (30 Hp negative, 30 Hp positive, 20 early gastric cancer patients, and 10 advanced gastric cancer patients), but also auxiliarily diagnose gastric cancer. Results Combined with multivariate statistical analysis, the results represented biomarkers different from Hp negative, Hp positive, and the alterations of metabolic phenotype of gastric cancer patients. Forty-three metabolites are involved in amino acid metabolism, and lipid and fatty acid metabolism pathways in the process of cancer occurrence, especially 2 biomarkers glycerophosphocholine and neopterin, were screened in this study. Neopterin was consistently increased with gastric cancer progression and glycerophosphocholine tended to consistently decrease from Hp negative to advanced gastric cancer. Conclusion This method could be used for the development of rapid targeted methods for biomarker identification and a potential diagnosis of gastric cancer.

Download Full-text